FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to field of pharmaceutics and medicine and deals with medication for treatment or prevention of diseases, mediated by mast cells, including neramexane or its pharmaceutically acceptable salt.
EFFECT: medication has high efficiency with respect to treatment or prevention of diseases, mediated by mast cells.
28 cl, 1 dwg, 17 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 1-AMINOALKYLCYCLOHEXANE DERIVATIVES FOR TREATMENT OF INFLAMMATORY SKIN DISEASES | 2009 |
|
RU2481828C2 |
| 1-AMINOALKYLCYCLOHEXANE DERIVATIVES FOR TREATING AND PREVENTING HEARING LOSS | 2008 |
|
RU2452476C2 |
| NEW COMBINATIONS OF NERAMEXANE FOR TREATING NEURODEGENERATIVE DISORDERS | 2008 |
|
RU2432161C1 |
| INTERVAL THERAPY FOR TREATING TINNITUS | 2008 |
|
RU2446794C2 |
| 1-AMINOALKYLCYCLOHEXANE DERIVATIVES FOR TREATING COCHLEAR TINNITUS | 2008 |
|
RU2438658C2 |
| NERAMEXANE TITRATION KIT AND USING IT IN TREATING INTERNAL EAR DISORDERS | 2008 |
|
RU2459618C2 |
| USE OF PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR TREATING SYSTEMIC MASTOCYTOSIS | 2006 |
|
RU2445960C2 |
| TYROSINE KINASE INHIBITOR OR ITS PHARMACEUTICAL SALT FOR TREATMENT OF SYSTEMIC MASTOCYTOSIS | 2016 |
|
RU2778337C2 |
| HYDRAZONO-MALONITRILES | 2002 |
|
RU2302412C2 |
| USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | 2014 |
|
RU2666219C2 |
